Status:
COMPLETED
A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi
Lead Sponsor:
Takeda
Conditions:
Von Willebrand Disease (VWD)
Eligibility:
All Genders
18+ years
Brief Summary
The main aim of this study is to estimate the risks of certain adverse events in adults with Von Willebrand Disease treated with VEYVONDI. No study medicines will be provided to participants in this s...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Participants with 18 years of age or older
- Participants with diagnosis of congenital VWD.
- Participants received VEYVONDI with or without a FVIII concentrate.
- Participants must have at least 7 days of observation time after the index dose.
- Provides informed consent, if required, in accordance with local ethical and institutional requirements. All medical record data will be abstracted retrospectively; therefore, an exemption or waiver of informed consent will be sought from all associated independent ethics committees (IECs) and institutional review boards (IRBs).
- Exclusion criteria:
- History of any other coagulation or platelet disorder (including acquired VWD).
- History of neutralizing antibodies / inhibitors to VWF or FVIII.
Exclusion
Key Trial Info
Start Date :
June 8 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 6 2023
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT05265078
Start Date
June 8 2022
End Date
April 6 2023
Last Update
August 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MVZ Gerinnungszentrum Hochtaunus
Bad Homburg, Hesse, Germany, 61352